Editorial Commentary:
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Ann Transl Med
.
2020 Aug;8(16):1037.
doi: 10.21037/atm.2020.03.217.
Authors
Mary E Westerman
1
,
Christopher G Wood
1
Affiliation
1
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
PMID:
32953837
PMCID:
PMC7475466
DOI:
10.21037/atm.2020.03.217
No abstract available
Publication types
Editorial
Comment